Actively Recruiting
Open-label Study for Continued Access to Gilead HIV Treatments in Children and Adolescents Who Completed Parent Clinical Studies
Led by Gilead Sciences · Updated on 2026-10-19
350
Participants Needed
15
Research Sites
352 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to provide continued access to study drugs for children and adolescents living with HIV-1 who have completed participation in certain prior clinical studies involving Gilead HIV treatments. The main goals are to allow these participants to keep receiving the study drug they were taking or switch to a specific combination drug called bictegraviremtricitabinetenofovir BFTAF, and to monitor the safety of these treatments. Participants will continue taking the study drugs they used in their parent studies, which may include various combinations of antiretroviral medications such as emtricitabinetenofovir alafenamide FTAF with a third agent, elvitegravircobicistatemtricitabinetenofovir alafenamide ECFTAF, or other combinations involving cobicistat and protease inhibitors. Dosages are adjusted based on the participants weight. Some participants may switch to BFTAF at a dose appropriate for their weight. During the study, participants will be monitored for adverse events and treatment safety over time. Researchers will measure how many eligible participants receive access to the study drugs and track any treatment-emergent side effects. The study may last up to several years, with ongoing assessments to ensure participant well-being and to collect safety data.
CONDITIONS
Brief Title
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
Research Team
G
Gilead Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here